UNIVERSITY OF CAMBRIDGE enterprise

/Where ideas **thrive**

Investor Information Sheet

Company Name:	**Spirea**
Funding Stage:	**Seed**
Investment Opportunity:	**£141k**
Web address	**www.spirea.co.uk**

SPIREA

Delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.

Spirea has developed an exciting and flexible new approach to building ADCs that allows more drug payload to be specifically directed to the tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects.

The Challenge: Antibody drug conjugates (ADCs) are cancer therapeutics in which drug payloads are chemically linked to antibodies in order to specifically target tumour cells.

Typically, ADCs are constrained by severe dose-limiting toxicities driven by the need to use highly toxic drug payloads to achieve sufficient clinical efficacy. This is reflected in only 12 approved ADCs emerging from an apparently promising preclinical pipeline.

The Solution: Spirea's patented high drug-to-antibody ratio linker technology permits the development of a next generation of ADCs incorporating a variety of payloads at varying levels of drug potency, antibody-drug loading and modes-of-action.

With this capability to create ADCs tailored to specific indications, Spirea will build highly differentiated ADCs with significantly better efficacy and safety profiles and will first address solid tumours where there is a very significant unmet need with existing therapeutics.

Milestones to date

2015	Company founded
2017/18	Started R&D activities to develop its ADC platform technology
Dec 2018	First ADC patent application filed
2019/2020	Successful construction of a high DAR ADC incorporating a marketed antibody targeting HER-2 and a drug payload used in market-approved ADCs.
2020/2021	Demonstrated the superiority of its DAR 16 ADC against Kadcyla (approved ADC) in a mouse tumour model. Demonstrated a 30-fold improvement in cell killing activity. Target-indications selected for pipeline.
2022	ADC patent granted in UK

Date	Source	Amount
February 2017	Judge Business School, Cambridge (Grant)	£10,000
June 2017	Royal Society of Chemistry (Grant)	£4,000
December 2017	Innovate UK (IUK) (Grant)	£104,122
	IPG (Convertible Loan) – IUK grant matching	£45,000
July 2018	IPG (Convertible Loan) – Follow-on	£105,000
December 2019	Cambridge Enterprise (Convertible Loan)	£75,000
April 2020	Start Codon Health Accelerator (Advanced Subscription)	£250,000
	Jonathan Milner (Advanced Subscription)	£200,000
November 2020	o2h Ventures (Equity)	£299,999
	Syndicate Room (Equity)	£43,239
May 2022	Jonathan Milner, Cambridge Enterprise, R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels (Equity)	£2,358,649
	TOTAL	£3,495,009

UNIVERSITY OF CAMBRIDGE
enterprise

/ Where ideas **thrive**

Investor Information Sheet

Funding Opportunity

Spirea is raising £141k as a second close on the £2.4M financing recently secured from Cambridge Enterprise, Jonathan Milner, US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and The Cambridge Angels.

The £2.4M raise provides a runway of 2 years during which the company will initiate a pipeline with a first programme in solid tumours. The Company will also generate additional data in support of its high DAR ADC strategy in line with feedback received from pharmaceutical companies and potential Series A investors. This includes the construction of new ADCs and the demonstration of superior efficacy, safety and PK vs. established comparator drugs in rodent models.

Specifically, the £141k that we are currently seeking will be used to recruit an additional senior scientific colleague to further strengthen the team and increase the likelihood of success.

Management Team

Myriam Ouberai, CEO



Myriam is the Founder, Chief Executive Officer of Spirea and the inventor of Spirea's technologies. Myriam has a PhD in Chemistry from Université Grenoble Alpes and has significant experience in drug delivery and biopharmaceuticals in both academia and industry. Prior to Spirea, Myriam was a Senior Postdoctoral Research Associate at University of Cambridge. In 2018, Myriam was selected as one of 50 Movers and Shakers in BioBusiness by UK biotech platform BioBeat, who described her as an inspiring and innovating leader.

Adam Collier, CBO

Adam is the Chief Business Officer of Spirea. Adam has over 15 years' experience in biotech management, business development & licensing and early-stage company formation. He holds a PhD in Virology from the University of Bath, an MBA from the Judge Business School, Cambridge and completed two postdoctoral research fellowships in oncology and virology before spending time as a drug discovery senior scientist at Vernalis Ltd in Cambridge. He has held several senior business development and management positions at Medimmune, Ablynx and Isogenica, and was a Founder-Director of Horizon Discovery Ltd.

References & Patents:

Spirea has a strong IP position with 4 patent families granted or in prosecution. Its ADC patents are written with broad claims on the linker composition for use with any antibody, drug payload and bioconjugation technology. They give wide coverage and will allow the development of multiple commercial products.

Link:

https://patents.google.com/?inventor=ouberai&oq=ouberai

For further information please contact:

Christine Martin
Head of Seed Funds

christine.martin@enterprise.cam.ac.uk

www.enterprise.cam.ac.uk